Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 Biomarker group BEFREE URGENTseq enables the reporting of selected genes useful for immediate diagnosis (CALR, CSF3R, JAK2, KRAS, MPL, NPM1, NRAS, SF3B1) and treatment decisions (IDH1, IDH2) in hematologic malignancies within 48 hours of specimen collection. 30577887 2019
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 Biomarker group BEFREE IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. 30455381 2019
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 GeneticVariation group BEFREE Since 2013, several mutant IDH-targeted inhibitors have been developed, and nearly a dozen clinical trials have opened specifically for IDH-mutant hematologic malignancies. 29064021 2017
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 GeneticVariation group BEFREE Inhibition of mutant IDH shows promise as a treatment approach in hematologic malignancies, with further development ongoing in solid tumors and glioma. 27005468 2016
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 Biomarker group BEFREE IDH1- and IDH2-mutant primary human AML cells were more sensitive than IDH1/2 wild-type cells to ABT-199, a highly specific BCL-2 inhibitor that is currently in clinical trials for hematologic malignancies, both ex vivo and in xenotransplant models. 25599133 2015
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 GeneticVariation group BEFREE Mutations in the IDH1 and IDH2 (isocitrate dehydrogenase) genes have been discovered across a range of solid-organ and hematologic malignancies, including acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma. 24760710 2014
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 GeneticVariation group BEFREE The importance of the TET-mediated cytosine demethylation pathway is also underscored by a recurrent mutation of isocitrate dehydrogenase 1 (IDH1) and IDH2 in hematological malignancies, whose mutation inhibits TET function through a novel oncometabolite, 2-hydroxyglutarate. 25040794 2014
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 Biomarker group BEFREE The somatic mutations of isocitrate dehydrogenase genes (IDH1 and IDH2) have been identified in a proportion of hematologic malignancies. 21997850 2012
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 Biomarker group BEFREE Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) were recently demonstrated in acute myeloid leukemia (AML), but their prevalence and prognostic impact remain to be explored in large extensively characterized AML series, and also in various other hematologic malignancies. 20538800 2010
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 GeneticVariation group BEFREE In this study, we screened the IDH1 and IDH2 mutations in a cohort of 456 Chinese patients with various hematological malignancies and disorders. 20946881 2010
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.400 CausalMutation group CGI